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Abstract: (250/250 words) 
 
Purpose of review: the number of HIV-exposed but uninfected (HEU) infants exposed to both HIV and 
multiple antiretroviral drugs in utero and during prolonged breastfeeding is increasing in low-income 
countries where HIV prevalence is the highest. We review recent evidence on the effects of 
perinatal/postnatal exposure to maternal HIV and combined antiretroviral therapy (cART) on health 
outcomes of HEU children (mitochondrial and metabolic toxicity, adverse pregnancy outcomes, 
neurodevelopment, growth, infectious morbidity and mortality). 
 
Recent findings: Several studies have reported ART-associated mitochondrial toxicity and metabolic 
disorders with conflicting results on adverse pregnancy outcomes, underscoring the need to conduct 
further investigations on these questions. Studies about congenital abnormalities report no significant 
differences between HEU exposed to ART and HIV-unexposed (HUU) children. Updated French data 
showed no significant difference in cancer incidence between HEU cART-exposed children and the 
general paediatric population. Furthermore, HEU children exposed to maternal cART have modest but 
significant impairment of development and a higher risk of growth impairment. Finally, HEU have higher 
risks of infections (mainly low respiratory tract infections and diarrhoea) and malaria than HUU children, 
particularly in children not breastfed or after early weaning. Higher mortality risk from infectious disease 
is reported in HEU compared to HUU children.  
 
Summary: As we move towards the elimination of MTCT, HEU children are an emerging population 
whose health outcomes remain to be fully described. Future large cohorts of HEU children using careful 
comparison groups of HUU in the post-ART era are needed to better understand their long-term health 
outcomes. 
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Introduction 
Antiretroviral therapy (ART) among HIV-infected pregnant women has dramatically decreased risk of 
mother-child-transmission worldwide, with the number of newly HIV-infected infants decreasing from 
570,000 in 1999 to 240,000 in 2013 (1). As a consequence of this success, the number of HIV-exposed 
but uninfected (HEU) infants exposed to both HIV and multiple antiretroviral drugs in utero and often 
during prolonged breastfeeding has increased in low-income countries where HIV prevalence is the 
highest (2). For this growing population, it is crucial to measure their short and long-term outcomes. 
There is some evidence that HEU African children are at increased risk of morbidity, early failure to 
thrive and mortality compared to HIV-unexposed uninfected (HUU) counterparts (3, 4). Appropriate 
comparisons of HEU and HUU were rare before the antiretroviral era. With increasing ART access, it is 
methodologically challenging to disentangle effects of HIV exposure from those associated with ART 
exposure, particularly in regions where malnutrition and co-morbidities are common and could increase 
the potential effects of these exposures. Few data are available so far on long-term effects in this 
context, and for obvious reasons there is no randomised clinical trial data to directly compare the 
effects of ART-exposure in HEU children. However, information from observational prospective cohorts 
provides useful evidence.  Our aim is to summarize recent evidence on the effects of perinatal/postnatal 
exposure to HIV and ART on health outcomes in children.   
Review: effects on health outcomes in HEU children  
1. Mitochondrial and metabolic toxicity attributable to ART exposure 
Multiple potential mechanisms of ART-associated mitochondrial toxicity in HEU infants have been 
proposed and several studies have identified toxicity markers, although findings regarding presence of 
clinical mitochondriopathy and mitochondrial DNA (mtDNA) levels in HEU children conflict (5). 
A study of 133 HEU, ART-exposed infants and 73 healthy controls in Spain investigated mitochondrial 
respiratory chain (MRC) function alongside mitochondrial mass (MM) during infancy. Although groups 
had similar MM, an inverse correlation between MM and MRC enzymatic activity of complex IV (CIV) 
was seen, with the latter significantly lower in HEU infants when accounting for MM. This difference 
remained significant at age 12 months, while no clinical manifestation of mitochondrial dysfunction was 
observed in HEU children (6). In a Cameroon study (38 HEU, 118 HUU infants), HEU infants with in 
utero/neonatal exposure to ZDV or NVP had significantly lower pre-prandial insulin levels at age 6 weeks 
than HUU infants in adjusted analyses (7); ZDV-exposed infants had higher insulin levels at higher fuel 
consumption levels than NVP-exposed infants, suggesting altered metabolism and greater insulin 
sensitivity. In a study in New-York State (infants born 2005-2008), more HEU ART-exposed infants had a 
positive screen for inborn errors of metabolism than HUU newborns (2.2% versus 1.2%, p=0.000025), 
with the pattern of metabolic disorders suggesting mitochondrial dysfunction mechanisms (8). In USA, 
zidovudine was associated with an increased risk of metabolic toxicity (RR:1.69; 95% Confidence Interval  
[CI]: 1.08-2.64) (9). 
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These findings underscore the need for further longitudinal studies to follow-up ART-exposed HEU 
children to explore persistence of metabolic abnormalities, clinical significance, and potential 
mechanisms. 
2. Adverse pregnancy outcomes, congenital abnormalities, cardiac effects and cancer 
In a meta-analysis (35 studies: 20 prospective cohorts, 12 retrospective cohorts, three case-control 
studies), HIV infection in women not receiving ART was clearly associated with preterm birth, low 
birthweight, small for gestational age (SGA), and stillbirth, especially in sub-Saharan Africa (10). Recent 
data on prevalence of congenital abnormalities in HEU children, and associations with in utero ART 
exposure are presented in Table 1, which are consistent with the literature to date, indicating a similar 
risk of defects as in the general population (11-20).  
Lack of clinically significant cardiac toxicity was reported from the US: comparison of left ventricular 
function and structure adjusted for age and body surface area between 417 HEU (95% cART-exposed) 
and 98 HUU controls aged 2-7 years showed no significant differences (21). Another study showed that 
prevalence and risk of ventricular septal defects and congenital heart defects among zidovudine-
exposed infants is not significantly different from that in infants exposed to non-zidovudine-containing 
regimens (16). However, sub-clinical findings associated with in utero cART-exposure were reported, 
requiring further prospective investigation.  
 The French Perinatal Cohort has presented updated information on incidence of cancers in >15,000 
HEU children exposed to ≥1 NRTI in utero with a median age of 9 years: although cancer incidence 
overall was not significantly different from the expected rate in the general paediatric population 
(standardized incidence ratio 0.8 [95%CI 0.47-1.24]), incidence among children exposed to didanosine 
was twice the rate expected (SIR = 2.5 [95%CI 1.01-5.19]) and associated with first trimester exposure 
(22). Nucleos(t)ide analogs can integrate into nuclear DNA and terminate DNA replication. A “genotoxic 
signature” in cord blood cells of ZDV+3TC-exposed neonates was reported in 2013 (23); in a subsequent 
study both ZDV and TDF exposure were associated with altered regulation of genes involved in DNA 
repair, DNA/RNA synthesis, cell cycle and telomere maintenance, with aneuploidy significantly increased 
in ZDV and TDF-exposed neonates versus controls. Aneuploidy may be a predisposing factor for cancer, 
but persistence of these genotoxic signatures over time and clinical implications remain unclear (24).  
3. Neurodevelopment 
Investigation of potential effects of in utero ART-exposure on neurodevelopment is complicated by the 
need to adjust for other factors including maternal substance use, socio-economic factors and other 
infections. Recent studies (Table 2) have adjusted for many of these confounders (25-29). In 2013, 
atazanavir was implicated in language delay in HEU children in the SMARTT study, but a later SMARTT 
study suggested that any effect may be transient as the increased risk of late language emergence at 
age 12 months was no longer apparent at age 24 months. Another study found no association between 
meconium atazanavir concentrations and late language emergence (Table 2). More recently, didanosine 
plus stavudine exposure was associated with an increased risk of both neurodevelopmental (RR = 12.40, 
95%CI 5.29-29.08) and language (RR = 4.84, 95%CI 1.14-20.51) delays (9).  A study conducted in Asia 
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demonstrated that HEU children have modest but significant impairment of development, particularly 
concerning language that needs to be investigated in terms of long-term significance (28).  
4. Growth 
The one study in the pre-ART era reported that anthropometric characteristics of HEU children were 
similar to those of HUU children over the first 18 months of life (30). Since then, there is evidence that 
early growth of HEU children in the first 3-6 months of life is poorer than that of their HUU counterparts 
without any consideration of ART exposure effects (31)(Table 3) (32-39).  HIV infection can directly 
contribute to disturbances in both growth and weight gain in early childhood (36).  At 6 months of age, 
anthropometric weight and height Z scores of HEU children were lower than those of HUU children in 
Zambian children participating in a trial of micronutrient-fortification after adjustment for treatment 
arm, socioeconomic factors, breastfeeding and gender (32).  In Ugandan infants, underweight was more 
frequent in HEU versus HUU children (adjusted OR 2.32; 95%CI 1.32, 4.09; P=0.006) but there was no 
evidence for an association with stunting or wasting (34). In a US cohort, growth of HEU and HUU 
children were similar over the first two years of life, but HEU infant birth weight was lower and HEU 
children had a pattern of slightly accelerated growth over this period. HEU children had less 
subcutaneous fat and decreasing mid-upper arm circumference over time when compared with US 
standards in the first two years of life (35). Recently, a comparative study of cohorts of HEU and HUU 
children aged 6-12 years in Zambia reported that although HEU children were smaller and had lower 
percent fat than HUU children, this appeared to be due mainly to their poorer socioeconomic status (33) 
(Table 3). Few studies on reversibility of early growth faltering in HEU children have been reported. In a 
before/after intervention study in Haiti, early growth faltering observed in HEU improved at 12 months 
of age after an intervention based on lipid-based nutrient supplementation, education, promotion of 
existing clinical services, and social support (39).  
Exposure to antiretroviral drugs perinatally could also affect growth among HEU children. However 
initial studies exploring these effects were reassuring. There are conflicting data about the effects of 
tenofovir use during pregnancy. Recently, tenofovir was reported to be associated with significantly 
lower neonatal bone mineral content (40), but not with increased risk of low birth weight or SGA (41, 
42). By most measures, in utero tenofovir-exposure did not significantly predict infant birth weight or 
growth through 6 months of age (43). However, ritonavir-boosted protease inhibitors have been 
associated with an independent higher risk of prematurity that has a confounding effect on growth (44). 
In a study pooling children from the Mashi and Mma Bana prospective cohorts in Botswana, excluding 
multiple and preterm births, cART-exposure was associated with lower birth weight compared to 
zidovudine exposure, with a rapid correction of the weight over the first 6 months of life (37). However, 
recent findings report after their 24-month follow-up, that in-utero cART-exposed compared to 
zidovudine-exposed children had significantly lower Length-for-Age (LAZ) and Weight-for-Age (WAZ) z-
scores (38). As poor growth impacts childhood and adult mortality, these findings raise concerns for 
potential lasting health impacts among HEU children with in-utero cART exposure.  
5.  Infectious disease morbidity and mortality 
For years, cohort studies from developing countries have reported that HEU infants have increased risk 
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of morbidity and mortality from infectious disease compared to HUU infants (45), often correlated with 
advanced maternal HIV disease, and maternal death (3, 46) (Table 4), (45, 47-57). A recent review 
identified 13 studies published in the past decade (58), where mortality rates in HEU infants ranged 
from 34/1000 in Malawi between 2004-2010 to 116/1000 child-years by 18 months in rural Uganda 
between 2002-2010 (34, 35).  The ZVITAMBO project in Zimbabwe was one of the largest studies to 
investigate this; the 2-year mortality rate was a three-fold higher in HEU compared to HUU (9.2% vs 
2.9%) and cause of death was mostly lower respiratory tract infection (45). High incidence of infectious 
morbidity and mortality has been repeatedly reported in HEU infants in low-resource settings (4, 45, 47-
52). Finally, in a recent systematic review, the mortality risk in HEU children compared to HUU children 
was about double at 24 months (pooled risk ratio:2.4 (95% CI: 1.1-5.1; I2=93%, three studies), although 
the association was not statistically significant at 12 months (46). Two recent publications from Europe, 
unfortunately without comparison to HUU group, have also reported a high incidence of severe 
infectious events occurring in HEU infants despite a low infectious disease burden (51, 52). The French 
Perinatal Cohort showed an association between serious bacterial infections occurring over the first 
year of life in HEU infants and maternal CD4 cell count <350 cells/μl (OR= 1.7 (95%CI 1.2-2.6 versus 
maternal CD4 >500) (52).  
Other studies have described more severe infections, more hospitalizations for infectious diseases, 
infections caused by uncommon pathogens, or pneumonia failing empiric treatment in HEU compared 
to HUU children (49, 59-61).  In Botswana, among children with pneumonia, HEU children had higher in-
hospital mortality rates compared to HUU children (49). Most infections reported involved the 
respiratory tract, and occurred in the first year of life peaking between 2 and 6 months of age (52, 60, 
62).  
Moreover, invasive infections due to encapsulated bacteria like group B Streptococcus (GBS) (48, 51, 63) 
and Streptococcus pneumoniae (53) were also more often observed in HEU infants (61).  GBS is the main 
cause of neonatal sepsis associated with a high mortality rate in Sub-Sahara Africa (64). Report from the 
South African nationwide invasive pneumococcal disease (IPD) laboratory surveillance showed that HEU 
infants had a three-fold greater risk of IPD than HUU infants over the first six months of life before and 
after implementation of pneumococcal vaccination (53). 
Absence of breastfeeding is associated with increased risk for infectious disease in early childhood in 
HEU infants. A recent cohort study in South Africa reported similar overall mortality rates in HEU and 
HUU infants, but among those who had never been breastfed, HEU infants had increased risk of 
mortality compared to HUU infants (54). In Uganda also, among infants aged 6-11 months non-breastfed 
HEU had a higher risk of hospitalizations, severe febrile illness, severe diarrhoea and severe malnutrition 
than non-breastfed HUU, whereas there were no differences of morbidity outcomes between breastfed 
HEU and HUU infants (47). Similar results were also reported in KwaZulu Natal, where exclusive 
breastfeeding was associated with fewer acute, persistent and total diarrheal events than mixed or no 
breastfeeding in both HEU and HUU infants (54). The Kesho-Bora study reported a seven-fold higher risk 
of death within 6 months in never breastfed or early-weaned HEU children compared to breastfed 
children (55).  Similarly, in a Zambian study an increased mortality risk in HEU infants was observed after 
weaning, ranging from a two-fold increase when weaning at 4-5 months of age to a 4.2 fold increase 
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when weaning at 12-18 months compared to weaning > 18 months (65). However, for HIV-infected 
mothers, it is well known that breastfeeding in the absence of cART places their HEU infant at risk of HIV 
infection and breastfeeding with cART will expose them to ARVs toxicities. A recent model-based 
analysis showed that optimal breastfeeding duration depends substantially on maternal HIV disease and 
availability of postnatal ARVs (66).  
6.  Mechanisms underlying susceptibility to infections 
ART-related mechanisms may include the depressed haematopoiesis, involving several lineages and 
persisting for several years, associated with perinatal exposure to nucleoside reverse transcriptase 
inhibitors (9, 10). Maternal HIV infection may also influence infant immune development (67, 68). 
Several studies have demonstrated reduced trans-placental transfer of maternal antibodies, reduced 
thymus output and functional defects of antigen-presenting cells in HEU infants. The mechanisms of 
these changes are unknown but might involve inflammatory responses at the placental level or trans-
placental transfer of HIV particles or soluble mediators with immunosuppressive properties. Owing to 
the close association of growth with immune function, an understanding of growth patterns is an 
important tool to ensure provision of appropriate care for HEU children. Altered immune responses to 
vaccination could also contribute to the higher rate of infection in HEU compared with HUU infants. In 
South Africa, although comparison of vaccine-specific antibody responses were equivalent in HEU and 
HUU infants, a large fraction of both groups had antibody titers below the protective levels over their 
first two years of life (69). In another study, significant, but transient, differences in cytokine production 
by mononuclear cells were detected between HEU and HUU infants (70). Their hypothesis was that time 
course of innate immune deviation early in life corresponds to the clinical window of vulnerability to 
infections in HEU infants and may be partially responsible for their increased morbidity and mortality 
from infectious disease. 
Discussion  
Recent studies have provided new evidence that HEU infants have poorer health outcomes than HUU 
infants, although some have acknowledged methodological weaknesses. Concerns remain regarding 
ART-associated mitochondrial toxicity and metabolic disorders, with a higher risk of metabolic disorder 
with zidovudine exposure (9). The data on congenital abnormalities is reassuring, but more research is 
needed to assess every individual drug and how ART regimens affect other perinatal outcomes. Some 
studies suggest neurological development impairment in HEU but longitudinal studies are warranted to 
examine the long-term clinical significance. HEU children exposed to maternal cART are at a higher risk 
of growth impairment during their first 24 months of life. Finally, HEU are at higher risk of morbidity and 
mortality from infectious disease compared to HUU. Evidence to date describing mortality in HEU 
infants is primarily from data from the pre-ART era, before the scale-up of PMTCT interventions and 
describes early infant mortality <2 years in breastfed populations (4).  Further studies are needed to 
evaluate long-term health outcomes in HEU-infants in the ART era. 
Many of the adverse outcomes associated with in utero HIV and cART exposure have multifactorial 
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aetiologies, but those related to HIV exposures could involve the environment of an HIV-affected 
household, including poor socio-economic conditions, increased maternal microbe carriage, and 
exposure to more infectious agents. Moreover, poor outcomes could simply be attributable to universal 
risk factors like low birthweight, prematurity, and small for gestational age that are also more prevalent 
in HEU not exposed to cART compared to HUU (10). Finally, maternal death, formula feeding and 
suboptimal breastfeeding practices clearly also reduce infant immune defences leading to a higher 
infectious disease morbidity (3, 46, 57). Adjustment for confounders is needed to ascertain properly the 
magnitude of the effects of HIV and cART exposure on health outcomes in HEU children. 
Conclusion 
To conclude, there is a need to better understand and assess the risks to health impairment associated 
with in utero and early life exposure to HIV and antiretroviral drugs in HEU children, particularly as these 
children become increasingly numerous. Ideally, long-term follow-up of large prospective cohorts of 
HEU children with careful comparative groups of HUU children should be constituted, but this poses key 
logistical and financial challenges.   
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Table 1: Summary of recent studies investigating congenital abnormalities in HEU infants 
Study Setting Subjects Key results Reference 
Ford et al, 2014 
Systematic review of 16 
studies reporting 
outcomes of 
cotrimoxazole exposure 
Global 4196 women (HIV positive 
and HIV negative) receiving 
cotrimoxazole during 
pregnancy 
Pooled prevalence of congenital defects = 3.5% (95% CI 1.8, 5.1%).   
Pooled prevalence for studies including women with 1st trimester 
exposure = 4.8% (95% CI 0.6%, 8.9%) 
Quality of the evidence was assessed to be very low (GRADE) 
(11) 
Ford et al, 2014 
Systematic review of 21 
studies reporting 
outcomes of 1st 
trimester EFV exposure 
Global 2026 live births among 
women exposed to 
efavirenz during the 1st 
trimester of pregnancy 
Pooled prevalence = 1.63% (95% CI 0.78, 2.48); 0.05% prevalence for 
neural tube defects  
One of 44 congenital defects was a neural tube defect 
No difference in risk of defects between efavirenz and non-efavirenz-
containing regimens received in 1st trimester (relative risk 0.78, 95% 
CI 0.56, 1.08) [12 studies] 
(12) 
Floridia et al, 2015 
Multi-site surveillance 
study of ART-exposed 
pregnancies 
Italy 1257 pregnancies with ART 
use ending in live birth, still 
birth, termination of 
pregnancy 
Prevalence = 3.2% (95% CI 1.9, 4.5) for 1st trimester exposure to any 
ART, 3.4% (95% CI 1.9, 4.9) for exposure in 2nd or 3rd trimester only.  
No associations between 1st trimester exposure to any ART, to any 
ART class or to EFV and major birth defects.  
(13) 
Liu et al, 2014  
Multi-site, pilot 
pregnancy ART registry 
South 
Africa 
and 
Zambia 
600 women conceiving on 
cART, October 2010 and 
April 2011 
Prevalence of major congenital anomaly = 2.2% (13/583)  (14) 
Vannappagari et al, 
2015,  
Antiretroviral 
Global 12 780 singleton birth 
outcomes with in utero ZDV 
exposure. Comparison 
exposure to ZDV-containing 
ARV regimens versus non-
RR for spontaneous abortions was 0.18 (95% confidence interval 
[95% CI] 0.14-0.22); induced abortions 0.28 (95% CI 0.22-0.36); 
stillbirths 0.76 (95% CI 0.51-1.12); premature births 1.00 (95% CI 0.87-
1.15) and LBW 1.17 (95% CI 1.02-1.33). 
(15) 
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Pregnancy Registry ZDV ARV regimens 
Vannappagari et al, 
2016,  
Antiretroviral 
Pregnancy Registry 
 15,451 live birth outcomes The prevalence of congenital heart defects was 0.60% (95% 
confidence interval: 0.47, 0.74) for infants exposed to zidovudine-
containing regimens and 0.50% (95% confidence interval: 0.26, 0.88) 
for non-zidovudine regimens. The relative risk comparing the 2 was 
1.18 (95% confidence interval: 0.64, 2.17). 
(16) 
William et al, 2015  
The Pediatric HIV/AIDS 
Cohort Study's 
Surveillance Monitoring 
of ART Toxicities 
(SMARTT) Study 
US 2580 HIV-exposed 
uninfected children 
In adjusted models, no association of first-trimester exposures with 
congenital abnormalities (CA) was found for any ARV, for 
combination ARV regimens, or for any drug class. No individual ARV in 
the reverse transcriptase inhibitor drug classes was associated with 
an increased risk of CAs. Among protease inhibitors, higher odds of 
CAs were observed for atazanavir sulfate (adjusted odds ratio [aOR], 
1.95; 95% CI, 1.24-3.05) and for ritonavir used as a booster (aOR, 
1.56; 95% CI, 1.11-2.20). With first-trimester atazanavir exposure, 
risks were highest for skin (aOR, 5.23) and musculoskeletal (aOR, 
2.55) CAs. 
(17) 
Sibiude et al, 2015 
Multi-site prospective 
French Perinatal Cohort 
France 12,888 live births in 1994-
2010 with in utero 
exposure to ART 
Overall rate of congenital heart defects (CHD)= 0.93% (95% CI 0.76, 
1.1%) 
Ventricular septal defects most common (75% of defects) 
1st trimester ZDV exposure associated with CHD (adjusted odds ratio 
2.2 (95% CI 1.5, 3.2)  
Four of 120 children with defects died due to heart failure 
(18) 
Sibiude et al, 2014 
Multi-site prospective 
French Perinatal Cohort 
France >10,000 live births from 
1994 to 2010 
Prevalence of congenital defects in infants with 1st trimester exposure 
ranged from 4.4% to 7.0% depending classification used 
A significant association was found between exposure to EFV in the 
1st trimester and neurological defects (adjusted odds ratio = 3.15), 
exposure to ZDV with congenital heart defects (aOR = 2.34), and 
(19) 
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didanosine, with head and neck birth defects (aOR = 2.89). 
Phiri et al, 2014  
Health insurance record 
linkage study 
United 
States 
806 infants (671 exposed to 
ART in utero, 221 with 1st 
trimester exposure) 
Prevalence of major birth defect = 4.0% (32/806) 
Prevalence in those with 1st trimester exposure = 4.1% (95% CI 1.5, 
6.7%) and 2nd/3rd trimester exposure = 4.4% (95% CI 2.5, 6.3%) 
No association between 1st trimester exposure to any ART or to any 
drug class and congenital defects  
(20) 
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Table 2: Recent studies assessing neurodevelopment in HEU children 
Study Setting Subjects Outcome Key results Reference 
Sirois et al, 
2013 
SMARTT 
USA 374 HEU infants with in 
utero exposure to ART 
and 49 HEU infants 
without exposure 
Bayley-III (cognition, language, motor 
skills, socio-emotional development and 
adaptive behaviour) at around 12 months 
of age 
No association between exposure to cART or any 
ART regimen in analyses adjusting for potential 
confounders; lower mean language score was 
reported in atazanavir-exposed infants including in 
sensitivity analyses without adjustment for preterm 
delivery or small-size-for-gestational-age. 
(25) 
Ngoma et al, 
2014 
Zambia 97 HEU with in utero 
and postpartum 
exposure (12 months) to 
ZDV+3TC+LPV/r and 103 
HUU children 
Capute Scales to assess non-verbal 
problem solving and language 
development. Developmental delay 
defined as Capute Full-Scale 
Developmental Quotient <85 
 
Developmental delay was found in 14.6% of HUU 
and 8.3% of HEU children. 
In adjusted analyses, low birthweight was the only 
risk factor for developmental delay 
(26) 
Rice et al, 
2013 
SMARTT 
USA 792 HEU children, 86% 
with in utero ART 
exposure 
Late language emergence (LLE). 
12 months: MacArthur-Bates 
Communicative Development Inventory 
(CDI). Age- and sex-adjusted percentiles 
in four domains with LLE defined as score 
≤10th percentile in any domain.  
24 months: the Communication scale of 
the Ages and Stages Questionnaire (ASQ), 
with LLE defined as total score ≥1 SD 
below the age-specific mean. 
26% of 12 month olds and 23% of two year olds had 
LLE. 
No significant differences in summary scores for CDI 
or ASQ by in utero exposure to cART or any ARV 
class were found in adjusted analyses.  
Atazanavir was associated with significantly 
increased risk of LLE at age 12 months, but not at 24 
months of age 
(27) 
Kerr et al, 
2014 
Thailand 
& 
160 HEU 6-8 years old 
children and 1678 HUU 
age and gender 
Wechsler Intelligence tests  
Stanford-Binet Intelligence Scales  
Children’s Behavior Checklist  
HEU children have modest but significant reductions 
in Verbal IQ, Full Scale IQ, and Bead Memory 
(assessed by Stanford Binet) compared to HUU 
(28) 
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PREDICT trial Cambodia matched controls CBCL syndrome based scales children  
Himes et al, 
2015 
SMARTT 
USA 175 HEU infants with in 
utero atazanavir 
exposure and a 
meconium sample 
available 
LEE according to CDI as above.  LEE risk was significantly lower in infants with higher 
meconium concentrations of atazanavir. 
 
(29) 
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Table 3: Summary of recent studies investigating growth in HEU infants 
 
Study Setting  Subjects Comparisons Key results Reference 
Filteau et al, 
2011 
Zambian 
cohorts post-
trial 
Zambia Children < 18 
months of age 
participating in a 
trial of 
micronutrient-
fortified 
125 HEU versus 
382 HUU 
In unadjusted analyses, most anthropometric Z scores of HIV-EU 
children were lower than those of HIV-unexposed children; after 
adjustment for treatment arm, socioeconomic factors, 
breastfeeding and sex, head and arm circumference Z scores 
remained lower. Subscapular skinfold Z scores were lower among 
HIV-EU than HIV-unexposed children at 6 months but not 18 
months. 
(32) 
Nicholson et al, 
2015  
Zambian 
prospective 
cohort studies 
Zambia HEU and HUU  111 HEU versus 
279 HUU children 
aged 6-12 years 
Anthropometric measures were lower among HEU than HUU 
children, significantly so for hip circumference (age- and sex-
adjusted difference -1.74 cm; 95% confidence interval (CI) -3.24, -
0.24; P = 0.023) and mid-upper-arm circumference (adjusted 
difference -0.63 cm, 95% CI -1.23, -0.04; P = 0.037) and with 
borderline effects for body mass index, thigh circumference and 
subscapular skinfolds. HEU children had significantly lower total, 
trunk, and limb fat percentages. All anthropometric and body 
composition differences became non-significant after adjustment 
for sociodemographic variables which differed between HEU and 
HUU children. All anthropometric and body composition 
differences became non-significant after adjustment for 
sociodemographic variables which differed between HEU and HUU 
children. 
(33) 
Muhangi et al, 
2013 
Ugandan 
cohorts 
Entebbe 
and 
Katabi 
sub-
county, 
1 year old HEU 
and HUU 
children  
122 HEU versus 
1380 HUU  
Underweight was significantly higher in HEU versus HUU children 
(adjusted OR52.32; 95% CI 1.32, 4.09; P=0.006) but no evidence for 
an association with stunting or with wasting. 
(34) 
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conducted 
before the ART 
era 
Uganda 
Neri et al, 2013 
US Cohort  
USA Children < two 
years old  
111 HEU versus 
82 HUU 
No statistical differences were found in anthropometric 
measurements between HEU and HUU. HEU were smaller than US 
standards at birth with mean (SD) weight-for-age and weight-for-
length z-scores of -0.39 (1.06); P = .002 and -0.35 (1.04); P = .005, 
respectively. Over the first 2 years of life, there was a trend toward 
increasing weight-for-age z-score, length-for-age z-score, and 
weight-for-length z-score in HEU. Subscapular and triceps skinfolds 
among HEU were lower than national standards and there was a 
trend that mid-upper arm circumference decreased over time. 
(35) 
Ramokolo et al, 
2014 
Prospective 
multisite cohort 
study in South 
Africa 
South 
Africa 
Children 
between 3 and 
36 weeks post-
partum 
In period 1 (3-24 
wk), 65 HIV-
infected, 502 HIV-
exposed 
uninfected (HEU), 
and 216 HIV-
unexposed infants 
were included. 
Mean weight velocity Z-scores (95% CI) was significantly (P < 0.001) 
lower in infected [-0.87 (-1.77, 0.04)] than HEU [0.81 (0.67, 0.94)] 
and unexposed [0.55 (0.33, 0.78)] infants. Length velocity Z-scores 
showed similar associations. 
(36) 
Powis et al, 
2011 
Follow-up of the 
Mashi and Mma 
Bana 
intervention 
trial 
Botswana full-term, HEU 
children 
breastfed until 6 
months 
619 exposed to 
maternal triple 
antiretrovirals 
(cART) versus 440 
zidovudine (ZDV) 
monotherapy 
exposed 
Mean birth weights were 3.01 kg for HAART and 3.15 kg for 
zidovudine-exposed infants (P < 0.001) with lower mean birth 
WAZ, length-for-age (LAZ), and weight-for-length (WLZ) among 
HAART-exposed infants (all P < 0.001). HAART-exposed infants had 
greater improvement in WAZ and weight-for-length (WLZ) from 
birth through 2 months (P = 0.03, P < 0.001, respectively). The WAZ 
did not differ between groups from 3 through 6 months (P = 0.26). 
Length-for-age (LAZ) remained lower in HAART-exposed infants but 
the incidence of wasting or stunting did not differ between 
exposure groups. 
(37) 
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Powis et al, 
2016 
Follow-up of the 
Mashi and Mma 
Bana 
intervention 
trial  
Botswana 819 singleton, 
full-term, HEU 
children 
breastfed until 6 
months 
516 exposed to in-
utero triple 
antiretrovirals 
(cART) versus 303 
zidovudine (ZDV) 
monotherapy 
exposed 
At 24 months, mean LAZ and WAZ were significantly lower among 
cART-exposed children (LAZ -1.01 versus -0.74; P = 0.003) (WAZ -
0.53 versus -0.30; P = 0.002) in unadjusted analyses. Adjusting for 
maternal CD4, viral load, enrolment site and maternal 
anthropometric measures, cART-exposed children had significantly 
lower LAZ and WAZ at 24 months (P = 0.0004 for both). At 24 
months, in-utero cART-exposed children had significantly lower 
LAZ and WAZ. 
(38) 
Heidkamp et al, 
2012 
Before/after 
intervention 
study on 
nutritional 
support during 
the first year of 
life 
Haiti non-breast-fed 
infants 6-12 
months of age 
attending 
GHESKIO 
pediatric clinic in 
Port-au-Prince, 
Haiti 
73 HEU exposed 
to intervention 
versus 294 HEU 
not exposed 
(historical control  
The intervention and historical control groups did not differ 
significantly at age 6 mo (wk 0). At age 12 mo (wk 24), the 
intervention group had a lower prevalence of underweight and 
stunting than the historical control group (weight-for-age Z-score < 
-2 SD: 6.8 vs. 20.8%, P = 0.007; length-for-age Z-score < -2 SD: 9.6 
vs. 21.2%, P = 0.029). Wasting tended to be lower in the 
intervention group than the historical control (weight-for-length Z-
score < -2 SD: 2.9 vs. 8.9%, P = 0.11). 
(39) 
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Table 4: Summary of recent studies investigating infectious disease and mortality in HEU infants 
Study Setting Subjects Comparison group Key results Reference 
Munyagwa M 
et al, 2012 
Prospective 
cohort 
Rural Uganda 
2002 – 2010 
206 HEU children 
recruited between 6 
weeks and 13 years 
89 HIV-infected 
infants 
Mortality rate among HEU was 1.3/100 person-years 
Predictors of mortality were a hospital admission 
since the 
last visit, and decreasing HAZ, WAZ or BMI-for-age Z 
score 
(47) 
Koyanagi A et 
al. 2011 
Prospective 
cohort within 
the 
ZITVAMBO 
trial 
Zimbabwe 2849 HEU recruited 
between 0-96 hours of 
age and followed-up up 
to 24 months 
9207 HUU Mortality among HEU was a 4-fold higher. HEU 
infants made an average of 30% more sick visits and 
20% more hospitalisations. 
(45) 
Epalza C et 
al, 2010 
 
Belgium 
2001 - 2008 
397 HEU newborns  20158 HUU 
newborns born in 
the same hospital 
and period 
Higher incidence of GBS sepsis among HEU infants, 
with a later onset suggesting an increased 
susceptibility in HEU 
(48) 
Kelly et al, 
2015 
Hospital-
based 
prospective 
cohort study 
Botswana 64 HEU children aged 1-
23 months with 
pneumonia 
153 HUU children 
aged 1-23 months 
with pneumonia 
HEU children with pneumonia had higher rates of 
treatment failure and in-hospital mortality during the 
first 6 months of life.  
(49) 
24 
 
Kourtis AP et 
al. 2013 
Prospective 
cohort within 
the BAN trial 
Malawi 2250 HEU recruited at 
birth exposed to 
maternal, infant, or no 
extended antiretroviral 
prophylaxis during 
breastfeeding 
None High rate of respiratory infections in infant early life; 
increases in the rate of respiratory infections, malaria 
and growth faltering after 6 months of life possible 
explained by early weaning. 
Infant cotrimoxazole prophylaxis was significantly 
associated with lower frequency of severe 
respiratory/other infectious and gastrointestinal 
morbidity, and of severe malaria 
(50) 
Adler et al, 
2015 
Retrospective 
cohort study 
Belgium 
 
527 HEU infants  None Incidence rate of severe infections was 16.8/100 
infant-years. 
Invasive pneumococcal disease was a 4-fold higher 
and group B streptococcus infection was 13-fold 
higher in these HEU compared to general population 
rates in Belgium 
(51) 
Taron-
Brocard et al, 
2014 
French 
Perinatal 
Cohort 
France 7638 HEU neonates None Association between lower maternal CD4 counts and 
risk of serious lower respiratory tract infections in 
HEU is constant over the first year of life. 
(52) 
Von 
Modlenforf 
et al, 2015 
South Africa Children aged <1 year laboratory- 
based surveillance 
database 
HEU children are twice as likely to have invasive 
pneumococcal disease associated hospitalisation and 
HEU children < 6 months are less likely to survive 
compared to HUU children. 
(53) 
Rollins et al, 
2013 
Non-
KwaZulu 
Natal, South 
Africa 
HEU and HUU exclusively 
breastfed infants 
HEU with 
replacement 
feeding.  
Higher morbidity and mortality among non-breastfed 
infants; longer duration of breastfeeding, the better 
the protection. 
(54) 
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randomised 
intervention 
cohort study  
No significant difference in the frequency of diarrheal 
events among exclusively breastfed infants between 
the HEU and HUU. 
  
Bork et al, 
2014 
Kesho Bora 
trial 
Kenya, 
Burkina Faso 
and South 
Africa 
751 HEU infants None Absence of breastfeeding was associated with only 
slightly increased risks of maternal-reported 
morbidity and 4- to 6-fold greater risks of serious 
infections 
(55) 
Kuhn et al, 
2010 
Early 
weaning trial 
(4 months vs 
time of 
choosing) 
cohort 
Zambia 747 HEU infants None The mortality rate was 9.4% by 12 months of age and 
13.6% by 24 months of age. Early weaning was 
associated with an increased risk of mortality  
 
 
(56) 
Marquez C et 
al, 2014 
Prospective 
cohort within 
the 
PROMOTE 
trial 
Uganda 200 HIV-exposed children 
aged 4–5 months 
400 HUU 13-fold higher risk of mortality and a higher risk of 
non-malarial morbidity among HEU children.  
(57) 
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Key points 
 The number of HEU infants exposed to both HIV and multiple antiretroviral drugs in 
utero and during prolonged breastfeeding has increased in low-income countries.  
 Recent studies have provided new evidence that HEU infants have poorer health 
outcomes than HUU infants. There are conflicting results about ART-associated 
mitochondrial toxicity, metabolic disorders and adverse pregnancy outcomes. There are 
reassuring results about congenital abnormalities. HEU children exposed to maternal 
cART have modest but significant impairment of development and growth. HEU have 
higher risks of infections than HUU children, particularly in children not breastfed or 
after early weaning and higher mortality risk from infectious disease.  
 Adjustment for confounders is needed to ascertain properly the magnitude of the effects 
of HIV and cART exposure on health outcomes in HEU children. 
 There is a need to conduct further investigations on HEU health outcomes. Long-term 
follow-up of large prospective cohorts of HEU children with careful comparative groups 
of HUU children should be constituted. 
 
 
